Form 4: Jasper Therapeutics COO Granted 90,000 Stock Options as Part of Retention Plan

Jasper Therapeutics, Inc.'s Chief Operating Officer, Jeetinder Singh Mahal, was granted 90,000 stock options with a $6 exercise price, vesting over four years.

Summary

• Jeetinder Singh Mahal, Chief Operating Officer of Jasper Therapeutics, Inc. (JSPR), was granted 90,000 stock options.
• The options have an exercise price of $6 per share.
• The transaction date for this grant was June 4, 2025.
• Vesting for these options begins on June 4, 2026, with 1/4th of the shares vesting on that date.
• Following the initial vesting, 1/48th of the shares will vest each month thereafter.
• The options are subject to Mr. Mahal's continuous service to the Issuer.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Mr. Mahal beneficially owns 90,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a neutral to slightly positive event, as it serves as a retention tool and aligns management's interests with shareholders. It does not, however, provide direct insight into operational performance or financial health.

Positives

• The grant of stock options aligns the Chief Operating Officer's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule acts as a retention mechanism for a key executive, ensuring continued leadership and stability.

Future Outlook

The vesting schedule of the stock options indicates a long-term commitment from the Chief Operating Officer to Jasper Therapeutics, with incentives tied to the company's future performance over the next several years.

Management Comments

• The filing itself represents a mandatory disclosure by the Chief Operating Officer regarding a change in beneficial ownership, reflecting the company's executive compensation practices.

Industry Context

The granting of stock options to key executives like the Chief Operating Officer is a standard practice in the biotechnology and pharmaceutical industries. It is a common form of executive compensation designed to attract, retain, and motivate talent by aligning their financial interests with the long-term success of the company.

Comparison to Industry Standards

• The structure of this stock option grant, including the exercise price relative to the current stock price (implied by the $6 exercise price, though current market price is not stated in the filing), and the multi-year vesting schedule, is consistent with typical executive compensation packages observed across the biotech and life sciences sectors.
• Comparable companies in the clinical-stage biotechnology space often utilize similar equity-based incentives to retain leadership, such as those seen at companies like CRISPR Therapeutics or Editas Medicine, where long-term equity grants are a significant component of executive pay.

Related Party Transactions

• The grant of stock options to the Chief Operating Officer is an insider transaction, which is a common form of compensation between the company and its executive management.

Stakeholder Impact

• Shareholders: The grant aims to align the COO's long-term interests with shareholder value creation, potentially leading to improved company performance.
• Employees: This grant is specific to a key executive, but similar equity incentives can be part of broader employee retention strategies.

Next Steps

• The stock options will begin to vest on June 4, 2026, and continue monthly thereafter, subject to the COO's continuous service.

Key Dates

Keywords

Jasper Therapeutics, JSPR, Stock Option, Executive Compensation, Insider Transaction, Form 4, Jeetinder Singh Mahal, Chief Operating Officer, Equity Grant, Vesting